Propanc Biopharma, a Nasdaq-listed biotech firm, has secured up to $100 million to bolster its digital asset strategy.
Related Posts
Ethereum upgrades may improve tech, but not investor confidence: Binance Research
Ethereum is facing ongoing issues with its tokenomics, and latest upgrades don’t address it.
These Are The Top 5 Bitcoin-Interested Countries According to Google
It has been over 15 years since Satoshi Nakamoto introduced Bitcoin to the world, and a lot has…
Analyst: Bitcoin resilience because of HODLers
A new wave of Bitcoin deleveraging began sometime in November, following the dawn of the FTX debacle. Many…